Samsung Biologics to acquire GSK’s US plant

Azernews.Az

22 December 2025 19:50 (UTC+04:00)

Samsung Biologics will acquire a drug manufacturing facility in the United States from GlaxoSmithKline (GSK) for $280 million, marking its first production foothold in the U.S. The move aims to enhance supply chain resilience amid rising biopharmaceutical trade barriers and tariff pressures from the United States, Azernews reports, citing Korean media.

Access to paid information is limited

Find the plan that suits you best.

1 month subscription

Full digital access to all news for 1 month

1.00₼

Select

3 months subscription

Full digital access to all news for 3 months

2.00₼

Select

-33%

6 months subscription

Full digital access to all news for 6 months

3.84₼

Select

-36%

1 year subscription

Full digital access to all news for 1 year

7.10₼

Select

-41%

Here we are to serve you with news right now. It does not cost much, but worth your attention.

Choose to support open, independent, quality journalism and subscribe on a monthly basis.

By subscribing to our online newspaper, you can have full digital access to all news, analysis, and much more.

You can also follow AzerNEWS on Twitter @AzerNewsAz or Facebook @AzerNewsNewspaper

Thank you!